PMID- 37855060
OWN - NLM
STAT- Publisher
LR  - 20231019
IS  - 1899-5276 (Print)
IS  - 1899-5276 (Linking)
DP  - 2023 Oct 19
TI  - Tumor suppressor miR-520a inhibits cell growth by negatively regulating PI3K/AKT 
      signaling pathway in acute myeloid leukemia.
LID - 10.17219/acem/171299 [doi]
AB  - BACKGROUND: Short regulatory RNAs, called microRNAs (miRNAs), have been found to 
      possess regulatory functions in cancer and, as such, have recently been evaluated 
      for their therapeutic role against various human malignancies. OBJECTIVES: The 
      present work aimed to investigate whether miR-520a can play a therapeutic role in 
      the treatment of human acute myeloid leukemia. MATERIAL AND METHODS: Human 
      myeloid leukemia cell lines (Kasumi-1, Kasumi-3, Kasumi-6, BDCM, and K562) and a 
      normal myeloid cell line (NCI-H5N6) were used for the study. Cell lines were 
      subjected to real-time quantitative polymerase chain reaction (RT-qPCR), 
      evaluation of cell viability and proliferation by MTT assay and colony formation 
      assays. Dual acridine orange (AO)/ethidium bromide (EB) staining was applied for 
      transfected K562 cells with miR-negative control (NC) or miR-520a mimics, and 
      annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) dual staining 
      and flow cytometry were performed to analyze cancer cell apoptosis followed by 
      western blot. RESULTS: Cancerous cell lines exhibited lower gene expression of 
      miR-520a, and its overexpression significantly reduced (p < 0.05) the 
      proliferation and viability of cancer cells. Cancer cells demonstrated the 
      induction of Bax/Bcl-2-mediated apoptosis following miR-520a overexpression. The 
      miR-520a was shown to target the PI3K/AKT signaling pathway in human acute 
      myeloid leukemia to exercise its regulatory role in cancer. CONCLUSIONS: The 
      study showed that miR-520a actively regulated cell proliferation in acute myeloid 
      leukemia and illustrated the mechanism by which it exerts its regulatory role, 
      emphasizing the possibility of targeting miR-520a as an efficient therapeutic 
      strategy against human acute myeloid leukemia.
FAU - Xiao, Jing
AU  - Xiao J
AD  - Department of Pathology, Renmin Hospital, Hubei University of Medicine, Shiyan, 
      China.
FAU - Wan, Fang
AU  - Wan F
AD  - Department of Pediatrics, Renmin Hospital, Hubei University of Medicine, Shiyan, 
      China.
FAU - Tian, Lin
AU  - Tian L
AD  - Department of Pathology, Renmin Hospital, Hubei University of Medicine, Shiyan, 
      China.
FAU - Li, Yao
AU  - Li Y
AD  - Department of Pathology, Renmin Hospital, Hubei University of Medicine, Shiyan, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20231019
PL  - Poland
TA  - Adv Clin Exp Med
JT  - Advances in clinical and experimental medicine : official organ Wroclaw Medical 
      University
JID - 101138582
SB  - IM
OTO - NOTNLM
OT  - AO/EB staining
OT  - acute myeloid leukemia
OT  - apoptosis
OT  - cell proliferation
OT  - microRNA
EDAT- 2023/10/19 06:45
MHDA- 2023/10/19 06:45
CRDT- 2023/10/19 04:30
PHST- 2023/03/23 00:00 [received]
PHST- 2023/04/10 00:00 [revised]
PHST- 2023/08/16 00:00 [accepted]
PHST- 2023/10/19 06:45 [medline]
PHST- 2023/10/19 06:45 [pubmed]
PHST- 2023/10/19 04:30 [entrez]
AID - 10.17219/acem/171299 [doi]
PST - aheadofprint
SO  - Adv Clin Exp Med. 2023 Oct 19. doi: 10.17219/acem/171299.